Arcadia Biosciences (RKDA) AI Stock Analysis

• Market Cap: $4.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: -1.80%
• EPS Growth: 15.74%
• Country: US
• Employees: 9
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): -0.85
• Shares Outstanding: 1,373,120
• 10 Day Avg. Volume: 3,254,407
• 30 Day Avg. Volume: 1,090,692
• PEG Ratio: 0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 1.60
• P/FCF Ratio: -0.84
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 0.74
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $4.00 ▲(24.61% Upside)

Arcadia Biosciences faces significant financial challenges, with declining revenue and ongoing unprofitability, which heavily impacts its overall score. Technical indicators provide a mixed outlook, with some potential for bullish momentum but no strong trend. The valuation is unattractive due to a negative P/E ratio and lack of dividends. These factors combine to result in a moderate overall stock score.

Positive Factors

Strong Equity Position

Arcadia's low debt-to-equity ratio highlights its strong equity position, providing financial stability and flexibility to invest in growth opportunities.

Proprietary Technology Platforms

Proprietary technology platforms give Arcadia a competitive edge in developing innovative agricultural products, supporting long-term growth and market differentiation.

Strategic Partnerships

Strategic partnerships enhance Arcadia's product development capabilities and market reach, fostering sustainable revenue streams and industry collaboration.

Negative Factors

Declining Revenue

Declining revenue suggests challenges in market demand or competitive positioning, potentially impacting long-term financial health and growth prospects.

Unprofitability

Ongoing unprofitability limits Arcadia's ability to reinvest in its business and may hinder future growth and operational resilience.

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and financial strain, potentially restricting Arcadia's ability to fund new initiatives and sustain operations.

Arcadia Biosciences Business Overview & Revenue Model

Company Description

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

How the Company Makes Money

Arcadia Biosciences generates revenue primarily through the commercialization of its proprietary crop varieties and technology licenses. The company earns money by selling seeds of its high-value crops, which are designed for better nutritional profiles and improved performance in various environmental conditions. Additionally, revenue is supplemented through collaborations and partnerships with other agricultural companies and research institutions, where they license their technology for use in developing new crop varieties. These partnerships often include upfront payments and milestone payments as products are developed, along with royalties on future sales. Strategic alliances with agricultural producers and distributors further enhance their market reach and revenue potential.

Arcadia Biosciences Financial Statement Overview

Summary

Arcadia Biosciences is facing financial challenges, particularly with profitability and cash flow generation. Revenue has declined, and the company remains unprofitable, although it has managed to maintain a strong equity position with minimal debt. The company needs to address its operational efficiency and cash flow management to improve its financial stability.

Income Statement

Arcadia Biosciences has faced challenges in maintaining revenue growth and profitability. The revenue decreased slightly from $5.33 million in 2023 to $5.045 million in 2024, indicating a revenue decline of approximately 5.35%. The gross profit margin improved slightly, but the company remains unprofitable with a negative net income for the year ending 2024. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a debt-to-equity ratio of 0.025, indicating low leverage. However, the return on equity remains negative due to consistent net losses. The equity ratio is 46%, indicating a solid equity position relative to total assets.

Cash Flow

Arcadia Biosciences experienced substantial free cash flow challenges, with negative free cash flow growth. Operating cash flow to net income ratio is negative, reflecting cash flow difficulties. However, cash flow from investing activities was positive, indicating some level of investment recovery.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.17M	5.04M	4.45M	7.42M	6.78M	8.03M
Gross Profit	1.96M	2.08M	2.28M	1.32M	-1.93M	2.83M
EBITDA	-4.09M	-7.50M	-5.73M	-14.75M	-27.71M	-5.44M
Net Income	-5.07M	-7.04M	-13.98M	-15.38M	-14.66M	-4.66M
Balance Sheet
Total Assets	8.58M	13.52M	19.70M	28.92M	43.92M	47.35M
Cash, Cash Equivalents and Short-Term Investments	5.88M	4.24M	11.64M	20.64M	28.68M	25.67M
Total Debt	0.00	155.00K	1.01M	2.02M	3.29M	9.35M
Total Liabilities	3.14M	7.29M	7.00M	8.02M	12.72M	18.80M
Stockholders Equity	5.44M	6.22M	12.84M	21.03M	31.09M	27.73M
Cash Flow
Free Cash Flow	-6.09M	-9.64M	-15.30M	-14.05M	-26.88M	-32.55M
Operating Cash Flow	-6.09M	-9.63M	-15.29M	-13.98M	-25.87M	-30.22M
Investing Cash Flow	3.27M	7.34M	-4.34M	1.42M	16.61M	17.28M
Financing Cash Flow	6.00K	9.00K	5.51M	4.52M	21.90M	20.56M

Arcadia Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Negative. The current price of 3.21 is below the 20-day moving average (MA) of 3.65, below the 50-day MA of 3.83, and below the 200-day MA of 3.90, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 33.48 is Neutral, neither overbought nor oversold. The STOCH value of 38.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RKDA.

Arcadia Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
RKDA	50 Neutral	$4.90M	-0.86	-64.08%	―	-1.80%	15.74%
BIOX	49 Neutral	$85.36M	-1.47	-20.52%	―	-27.90%	-4194.67%
SEED	46 Neutral	$15.54M	-19.13	―	―	-21.82%	-104.92%
AVD	45 Neutral	$110.46M	-1.02	-40.84%	―	-4.29%	-276.74%
LVRO	44 Neutral	$75.63M	-0.40	―	―	―	―
BHST	41 Neutral	$125.73M	-7.85	-200.22%	―	45.88%	43.12%

Arcadia Biosciences Corporate Events

Arcadia Biosciences Announces 2025 Annual Meeting Date

Arcadia Biosciences, Inc. has announced that its 2025 annual meeting of stockholders will be held on December 19, 2025. The company has also informed stockholders of a change in the meeting date and updated deadlines for submitting proposals and nominations for the meeting. This announcement follows a Securities Exchange Agreement with Roosevelt Resources, LP, which involves an all-stock transaction for the combination of the two companies. The meeting and the proxy statement are separate from the special meeting related to this transaction.